What you’ll learn on this page:
- The warnings and precautions for Infilbray are suicidal ideation and behavior, lens opacification in pediatric patients, and embryofetal toxicity1
- The most common adverse reactions were diarrhea, splenomegaly, nausea, depression, gastroenteritis, and vomiting1
- The safety profile from the pivotal study in patients with Gaucher disease type 31
Infilbray safety profile1
Infilbray warnings and precautions
Suicidal ideation and behavior
Suicidal ideation and behavior have been reported in patients with Gaucher disease type 3 receiving Infilbray and in unapproved populations receiving another oral formulation of venglustat, both with and without a history of psychiatric disorders.
Assess patients’ underlying risk of psychiatric disorders prior to treatment initiation and monitor for depressive symptoms or suicidal thoughts during treatment with Infilbray. Use caution when prescribing Infilbray to patients with a history of psychiatric disorders. Inform patients or caregivers of the potential for behavioral and mood changes and encourage them to seek medical attention for manifestations of suicidal ideation and behavior, new onset or worsening depression, or other mood changes. Consider changing the therapeutic regimen, including possibly discontinuing Infilbray, if such events occur.
Lens opacification in pediatric patients
Lens opacification may occur in pediatric patients treated with Infilbray. In pediatric patients, perform ophthalmological assessment prior to initiation and annually during treatment. Advise pediatric patients and caregivers to report any visual disturbances during treatment.
Embryofetal toxicity
Based on findings from animal studies, Infilbray may cause fetal harm when administered to a pregnant woman. Prior to initiation, verify pregnancy status in females of reproductive potential and advise them of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 11 days after the last dose.
Infilbray adverse reactions
Adverse reactions in Infilbray-treated adults and pediatric patients aged 12 to <18 years with Gaucher disease type 3 during the 52-week primary analysis period of the pivotal triala
|
Adverse reactions |
Infilbray
|
Imiglucerase
|
|
Diarrhea |
3 (14%) |
0 |
|
Splenomegaly |
3 (14%) |
0 |
|
Nausea |
3 (14%) |
1 (5%) |
|
Depression |
2 (10%) |
0 |
|
Gastroenteritis |
2 (10%) |
0 |
|
Vomiting |
2 (10%) |
1 (5%) |
aAdverse reactions occurring at an incidence of ≥10% in Infilbray-treated patients and greater than in imiglucerase-treated patients.
In a placebo-controlled, pooled analysis of safety data from 362 adult patients exposed to another formulation of venglustat in unapproved populations, depression occurred in 7.7% of patients (n=28) who received venglustat 15 mg orally once daily for a median duration of 52 weeks compared to 5.7% of patients (n=19) who received placebo (n=340). Suicidal ideation and behavior events occurred in 1% (n=4) of venglustat-treated patients compared to none in placebo patients.
The adverse reaction profile observed in pediatric patients (aged 12 to <18 years) did not appear to be different from that observed in adults.1
Frequently asked questions
Interested in learning more?
Relevant pages to view:
Indication
References: 1. Infilbray (venglustat). Prescribing information. Genzyme Corporation, Cambridge, MA. 2. Tylki-Szymańska A et al. J Inherit Metab Dis. 2010;33(4):339-346.
